Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Biocraft cephalexin ITC decision

Executive Summary

International Trade Commission agreed unanimously on Aug. 3 that cephalexin imports from Canada are not causing material injury to the domestic generic cephalexin manufacturers. However, in June, the Commerce Department imposed a 7.5% weight-averaged dumping margin on all Canadian cephalexin capsules. Biocraft filed a complaint in October 1988 alleging that cephalexin capsules imported from Canada by Lyphomed/Novopharm were being sold in the U.S. at a less than fair value and were materially injuring the industry. Meanwhile, Biocraft filed similar complaints July 12 against companies importing cephalexin capsules from Portugal and Israel. Biocraft and the importing companies Companhia Industrial Productora de Antibiotics (CIPAN) and Teva Pharmaceuticals appeared before the commission on Aug. 4.
Advertisement
Advertisement
UsernamePublicRestriction

Register

PS016022

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel